PTC THERAPEUTICS INC

NASDAQ: PTCT (PTC Therapeutics, Inc.)

Last update: 07 Nov, 10:40PM

71.78

-0.81 (-1.12%)

  • 1D -1.12%
  • 5D -4.23%
  • 1M 6.86%
  • 6M 55.33%
  • YTD 56.45%
  • 1Y 67.36%
  • 5Y 15.33%
Previous Close 72.59
Open 72.16
Volume 1,120,333
Avg. Volume (3M) 1,244,117
Market Cap 5,763,094,528
Price / Earnings (TTM) 8.35
Price / Sales 3.59
52 Weeks Range
35.95 (-49%) — 73.98 (3%)
Earnings Date 4 Nov 2025
Profit Margin 33.56%
Operating Margin (TTM) 82.43%
Diluted EPS (TTM) 6.39
Quarterly Revenue Growth (YOY) 459.70%
Current Ratio (MRQ) 3.89
Operating Cash Flow (TTM) 691.65 M
Levered Free Cash Flow (TTM) 526.00 M
Return on Assets (TTM) 24.42%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock PTC Therapeutics, Inc. Bullish Bullish

AIStockmoo Score

0.1
Analyst Consensus 1.5
Insider Activity -2.5
Price Volatility -4.0
Technical Moving Averages 1.5
Technical Oscillators 4.0
Average 0.10

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
PTCT 6 B - 8.35 -
RVMD 14 B - - 8.54
VRNA 9 B - - 33.01
CDTX 7 B - - 16.20
AKRO 4 B - - 4.67
IMVT 4 B - - 8.01

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 2.40%
% Held by Institutions 101.06%
52 Weeks Range
35.95 (-49%) — 73.98 (3%)
Price Target Range
50.00 (-30%) — 118.00 (64%)
High 118.00 (Cantor Fitzgerald, 64.39%) Buy
Median 76.00 (5.88%)
Low 50.00 (Goldman Sachs, -30.34%) Sell
Average 78.25 (9.01%)
Total 4 Buy, 3 Hold, 1 Sell
Avg. Price @ Call 69.31
Firm Date Target Price Call Price @ Call
Barclays 06 Nov 2025 68.00 (-5.27%) Hold 72.59
Citigroup 05 Nov 2025 75.00 (4.49%) Hold 71.77
Goldman Sachs 05 Nov 2025 50.00 (-30.34%) Sell 71.77
RBC Capital 05 Nov 2025 82.00 (14.24%) Buy 71.77
TD Cowen 05 Nov 2025 63.00 (-12.23%) Hold 71.77
Wells Fargo 05 Nov 2025 93.00 (29.56%) Buy 71.77
Jefferies 28 Oct 2025 77.00 (7.27%) Buy 67.49
Cantor Fitzgerald 03 Sep 2025 118.00 (64.39%) Buy 55.55
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BOULDING MARK ELLIOTT - 75.60 -2,812 -212,587
REEVE EMMA - 74.95 -7,333 -549,608
Aggregate Net Quantity -10,145
Aggregate Net Value ($) -762,196
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 75.28
Name Holder Date Type Quantity Price Value ($)
BOULDING MARK ELLIOTT Officer 17 Nov 2025 Automatic sell (-) 2,812 75.60 212,587
BOULDING MARK ELLIOTT Officer 17 Nov 2025 Option execute 2,812 - -
REEVE EMMA Director 12 Nov 2025 Automatic sell (-) 7,333 74.95 549,608
REEVE EMMA Director 12 Nov 2025 Option execute 7,333 - -

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria